JOYCLU Drug Insight and Market Forecast - 2032

This “JOYCLU Drug Insight and Market Forecast - 2032” report provides comprehensive insights about JOYCLU for osteoarthritis in the six major markets. A detailed picture of the JOYCLU for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the JOYCLU for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JOYCLU market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary

JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. JOYCLU is the first ethical drug indicated for hip joint OA in Japan among the joint function improvement agents. JOYCLU is approved for OA treatment (knee joint and hip joint) and is expected to improve OA symptoms. Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered low. JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Further, since JOYCLU is administered directly into the joint cavity as an injectable treatment, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is thought to be low. Ono Pharmaceutical and Seikagaku aim to contribute to the improvement of quality of life (QOL) in patients by providing a new treatment option for OA (knee joint and hip joint)

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the JOYCLU description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on JOYCLU regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JOYCLU research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around JOYCLU.
• The report contains forecasted sales of JOYCLU for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for JOYCLU in osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JOYCLU Analytical Perspective

In-depth JOYCLU Market Assessment

This report provides a detailed market assessment of JOYCLU for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

JOYCLU Clinical Assessment

The report provides the clinical trials information of JOYCLU for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JOYCLU dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to JOYCLU and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JOYCLU in osteoarthritis.
• This in-depth analysis of the forecasted sales data of JOYCLU from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JOYCLU in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of JOYCLU?
• What is the clinical trial status of the study related to JOYCLU in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JOYCLU development?
• What are the key designations that have been granted to JOYCLU for osteoarthritis?
• What is the forecasted market scenario of JOYCLU for osteoarthritis?
• What are the forecasted sales of JOYCLU in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to JOYCLU for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

This product will be delivered within 2 business days.